GO
Loading...

Regeneron Pharmaceuticals Inc

More

  • *Twitter rallies after blockbuster results. NEW YORK, July 30- U.S. stocks were flat on Wednesday, paring earlier gains as a strong read on second-quarter economic growth sparked concerns the Federal Reserve may adjust its stimulus earlier than expected.

  • *Twitter rallies after blockbuster results. *Biotechs rally on Amgen results, Regeneron trial data. Twitter Inc surged on heavy volume, jumping 25 percent to $48.25 in its biggest one-day advance ever after reporting that monthly active users had risen a better-than-expected 24 percent in the second quarter.

  • Early movers: UNH, BAC, IBM, COST, LL, WDFC & more Thursday, 10 Jul 2014 | 7:48 AM ET
    Traders on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Cramer: 4 strong stocks for months to come Wednesday, 9 Jul 2014 | 6:29 PM ET

    If the charts are to be believed, the path of least resistance for these 4 stocks should be higher.

  • Midday movers: Lorillard, PetSmart, Walgreen & More Thursday, 3 Jul 2014 | 11:58 AM ET

    Some of Thursday's midday movers:

  • Cramer: Six buyable themes in second half Tuesday, 1 Jul 2014 | 6:08 PM ET
    Jim Cramer on Mad Money.

    Cramer says the price action in Tuesday’s market is sending an important message about what to buy in the days ahead.

  • Midday movers: Alstom, CarMax, Sprint & More Friday, 20 Jun 2014 | 11:34 AM ET

    Some of Friday's midday movers:

  • Beleaguered biotechs about to rally: Charts Wednesday, 4 Jun 2014 | 6:26 PM ET

    For the past several months biotech stocks have fallen out of favor on Wall Street. That may be about to change.

  • Valeant's New York- listed shares dropped 1 percent by midday to $128.66, paring earlier losses, while Allergan stock lost 4.1 percent to $158.29. Valeant on Wednesday offered to pay $58.30 per Allergan share in cash, about $10 higher than its previous offer of $48.30.

  • Valeant increases bid for Botox-maker Allergan Wednesday, 28 May 2014 | 12:09 PM ET
    Botox by Allergan

    Canadian drugmaker Valeant Pharmaceuticals International raised the cash component of its offer for Botox-maker Allergan by $10 per share.

  • UPDATE 2-Valeant injects cash into bid for Botox maker Wednesday, 28 May 2014 | 9:06 AM ET

    Valeant on Wednesday offered to pay $58.30 per Allergan share in cash, about $10 higher than its previous offer of $48.30. The new offer values Allergan at $166.16 per share as of Tuesday's closing price, and is about 8.6 percent higher than the previous bid of $153 as on April 22 when Valeant first made its offer.

  • Valeant on Wednesday offered to pay $58.30 per Allergan share in cash, about $10 higher than its previous offer of $48.30. The new offer values Allergan at $166.16 per share as of Tuesday's closing price, and is about 8.6 percent higher than the previous bid of $153 as on April 22 when Valeant first made its offer.

  • TIMELINE-Early signs of pushback over U.S. drug prices Wednesday, 28 May 2014 | 1:00 AM ET

    May 28- Gilead Sciences' $84,000 treatment for hepatitis C, Sovaldi, has broken the sales record for drug launches and caused a backlash among insurers concerned by the cost.

  • Top 10 highest paid CEOs Tuesday, 27 May 2014 | 7:42 AM ET
    Les Moonves, president and chief executive officer of CBS Corp.

    Here are the 10 highest-paid CEOs of 2013, as calculated by The Associated Press and Equilar, an executive pay research firm.

  • May 19- Ophthotech Corp said it could potentially receive over $1 billion in payments as part of a licensing deal for its experimental eye drug with Novartis AG. Ophthotech's shares rose as much as 29 percent in trading after the bell.

  • ANALYSIS-Pfizer-AstraZeneca deal not quite dead yet Monday, 19 May 2014 | 6:36 PM ET

    NEW YORK, May 19- Pfizer Inc may have called its $118 billion bid for AstraZeneca Plc a "final" offer, and its British rival sees no prospect of a deal being revived. Morningstar analyst Damien Conover in Chicago said the odds of an AstraZeneca purchase had fallen well below the 50 percent mark.

  • Midday movers: NFLX, PCLN, BIIB & more Thursday, 15 May 2014 | 12:23 PM ET
    NYSE exchange floor

    Take a look at some of Thursday's midday movers:

  • Midday movers: Aaron's, Eli Lilly, Gogo & More Monday, 12 May 2014 | 12:30 PM ET
    NYSE EuroNext flag hangs outside the NYSE.

    Some of Monday's midday movers:

  • Even biotechs blame the weather Thursday, 8 May 2014 | 12:49 PM ET

    It's been a gloomy week for biotech earnings, and many have blamed their poor results on, of all things, the weather.

  • May 8- U.S. sales of Regeneron Pharmaceuticals Inc's eye drug Eylea missed market estimates due to a drop in distributor inventory and a severe U.S. winter that prevented patients from visiting clinics to receive the treatment. Sales of the drug outside the United States increased more than three-fold, to $218 million.